Today, cancer stage (TNM), age, performance status, and histology have been expanded with programmed-death ligand-1 (PD-L1) expression and the absence or presence of a targetable oncogenic driver as factors that may impact treatment decisions in non-small cell lung cancer (NSCLC). Here, CD274 is linked to non-small cell lung carcinoma.